These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11353638)

  • 21. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan.
    Cheng NC; Hsueh PR; Liu YC; Shyr JM; Huang WK; Teng LJ; Liu CY
    Microb Drug Resist; 2005; 11(4):330-41. PubMed ID: 16359192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ertapenem: a new carbapenem.
    Odenholt I
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains.
    Jones RN
    J Chemother; 2001 Aug; 13(4):363-76. PubMed ID: 11589478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira M; Jones RN; Livermore DM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.
    Friedland IR; Isaacs R; Mixson LA; Motyl M; Woods GL
    Diagn Microbiol Infect Dis; 2002 May; 43(1):61-4. PubMed ID: 12052630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
    Behra-Miellet J; Dubreuil L; Calvet L
    Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
    Friedland I; Mixson LA; Majumdar A; Motyl M; Woods GL
    J Chemother; 2002 Oct; 14(5):483-91. PubMed ID: 12462428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1915-8. PubMed ID: 11353653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.
    Brown SD; Traczewski MM
    J Clin Microbiol; 2007 Jul; 45(7):2173-9. PubMed ID: 17494717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
    Lascols C; Legrand P; Mérens A; Leclercq R; Muller-Serieys C; Drugeon HB; Kitzis MD; Reverdy ME; Roussel-Delvallez M; Moubareck C; Brémont S; Miara A; Gjoklaj M; Soussy CJ
    Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
    Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Multicenter study of the in vitro effect of imipenem (N-formimidoyl-thienamycin) on hospital bacteria].
    Soussy CJ; Otterbein G; Le Van Thoi J; Thabaut A; Meyran M; Courtieu AL; Reynaud A; Dabernat H; Lareng MB; Chanal M
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):487-92. PubMed ID: 3911142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.
    Pankuch GA; Davies TA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2002 Jan; 46(1):42-6. PubMed ID: 11751109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2001 Jul; 48(1):23-8. PubMed ID: 11418509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
    Hilliard NJ; Johnson CN; Armstrong SH; Quarles S; Waites KB
    Int J Antimicrob Agents; 2002 Aug; 20(2):136-40. PubMed ID: 12297363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
    Hoellman DB; Kelly LM; Credito K; Anthony L; Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2002 Jan; 46(1):220-4. PubMed ID: 11751138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006].
    Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
    Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
    Pelak BA; Citron DM; Motyl M; Goldstein EJ; Woods GL; Teppler H
    J Antimicrob Chemother; 2002 Nov; 50(5):735-41. PubMed ID: 12407133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.